Hormone treatment, estrogen receptor polymorphisms and mortality: A prospective cohort study

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Ryan, Joanne ^a   Canonico, Marianne ^b   Carcaillon, Laure ^b,c   Carrière, Isabelle ^a   Scali, Jacqueline ^a   Dartigues, Jean Francois ^c   Dufouil, Carole ^c   Ritchie, Karen ^a,d   Scarabin, Pierre Yves ^b   Ancelin, Marie Laure ^a  

^a INSERM U1061   (France)

^b CENTRE FOR RESEARCH IN EPIDEMIOLOGY AND POPULATION HEALTH   (France)

^c INSERM   (France)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; ESTROGEN RECEPTOR; GESTAGEN;

AGE; AGED; ALLELE; ARTICLE; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DEPRESSION; DRUG FATALITY; EDUCATION; FEMALE; FOLLOW UP; FRANCE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HOMOZYGOSITY; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; NEOPLASM; POPULATION RESEARCH; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; TREATMENT DURATION; GENETICS; HORMONE SUBSTITUTION; MORTALITY;

AGED; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MORTALITY; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; RECEPTORS, ESTROGEN;

EID: 84858773315     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0034112     Document Type: Article

References (47)

1. Freeman EW, Sherif K, (2007) Prevalence of hot flushes and night sweats around the world: a systematic review. Climacteric 10: 197-214.
2. Welton AJ, Vickers MR, Kim J, Ford D, Lawton BA, et al. (2008) Health related quality of life after combined hormone replacement therapy: randomised controlled trial. BMJ 337: a1190.
3. Farquhar C, Marjoribanks J, Lethaby A, Suckling JA, Lamberts Q, (2009) Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev 15: CD004143.
4. Canonico M, Oger E, Plu-Bureau G, Conard J, Meyer G, et al. (2007) Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 115: 840-845.
5. Cauley JA, Seeley DG, Browner WS, Ensrud K, Kuller LH, et al. (1997) Estrogen replacement therapy and mortality among older women. The study of osteoporotic fractures. Arch Intern Med 157: 2181-2187.
6. Paganini-Hill A, Corrada MM, Kawas CH, (2006) Increased longevity in older users of postmenopausal estrogen therapy: the Leisure World Cohort Study. Menopause 13: 12-18.
7. Petitti DB, Perlman JA, Sidney S, (1987) Noncontraceptive estrogens and mortality: long-term follow-up of women in the Walnut Creek Study. Obstet Gynecol 70: 289-293.
8. Rodriguez C, Calle EE, Patel AV, Tatham LM, Jacobs EJ, et al. (2001) Effect of body mass on the association between estrogen replacement therapy and mortality among elderly US women. Am J Epidemiol 153: 145-152.
9. Chilvers CE, Knibb RC, Armstrong SJ, Woods KL, Logan RF, (2003) Post menopausal hormone replacement therapy and risk of acute myocardial infarction-a case control study of women in the East Midlands, UK. Eur Heart J 24: 2197-2205.
10. Grodstein F, Manson JE, Stampfer MJ, (2006) Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J Womens Health (Larchmt) 15: 35-44.
11. Sourander L, Rajala T, Raiha I, Makinen J, Erkkola R, et al. (1998) Cardiovascular and cancer morbidity and mortality and sudden cardiac death in postmenopausal women on oestrogen replacement therapy (ERT). Lancet 352: 1965-1969.
12. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, et al. (2004) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 291: 1701-1712.
13. Cherry N, Gilmour K, Hannaford P, Heagerty A, Khan MA, et al. (2002) Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial. Lancet 360: 2001-2008.
14. Hulley S, Grady D, Bush T, Furberg C, Herrington D, et al. (1998) Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 280: 605-613.
15. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, et al. (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 288: 321-333.
16. Vickers MR, MacLennan AH, Lawton B, Ford D, Martin J, et al. (2007) Main morbidities recorded in the women's international study of long duration oestrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women. BMJ 335: 239.
17. Rossouw JE, Prentice RL, Manson JE, Wu L, Barad D, et al. (2007) Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 297: 1465-1477.
18. L'Hermite M, Simoncini T, Fuller S, Genazzani AR, (2008) Could transdermal estradiol+progesterone be a safer postmenopausal HRT? A review. Maturitas 60: 185-201.
19. Schumacher M, Guennoun R, Ghoumari A, Massaad C, Robert F, et al. (2007) Novel perspectives for progesterone in hormone replacement therapy, with special reference to the nervous system. Endocr Rev 28: 387-439.
20. Prentice RL, Langer R, Stefanick ML, Howard BV, Pettinger M, et al. (2005) Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the Women's Health Initiative clinical trial. Am J Epidemiol 162: 404-414.
21. Gompel A, Rozenberg S, Barlow DH, (2008) The EMAS 2008 update on clinical recommendations on postmenopausal hormone replacement therapy. Maturitas 61: 227-232.
22. Hodis HN, Mack WJ, (2009) Coronary heart disease and hormone replacement therapy after the menopause. Climacteric 12 (Suppl 1): 71-75.
23. Abbas S, Brauch H, Chang-Claude J, Dunnebier T, Flesch-Janys D, et al. (2010) Polymorphisms in genes of the steroid receptor superfamily modify postmenopausal breast cancer risk associated with menopausal hormone therapy. Int J Cancer 126: 2935-2946.
24. Herrington DM, Howard TD, Hawkins GA, Reboussin DM, Xu J, et al. (2002) Estrogen-receptor polymorphisms and effects of estrogen replacement on high-density lipoprotein cholesterol in women with coronary disease. N Engl J Med 346: 967-974.
25. Silvestri S, Thomsen AB, Gozzini A, Bagger Y, Christiansen C, et al. (2006) Estrogen receptor alpha and beta polymorphisms: is there an association with bone mineral density, plasma lipids, and response to postmenopausal hormone therapy? Menopause 13: 451-461.
26. Almeida S, Hutz MH, (2007) Genetic variation of estrogen metabolism and the risks of cardiovascular disease. Curr Opin Investig Drugs 8: 814-820.
27. Katzenellenbogen BS, (1980) Dynamics of steroid hormone receptor action. Annu Rev Physiol 42: 17-35.
28. Herrington DM, (2003) Role of estrogen receptor-alpha in pharmacogenetics of estrogen action. Curr Opin Lipidol 14: 145-150.
29. The 3C Study Group (2003) Vascular factors and risk of dementia: Design of the three city study and baseline characteristics of the study population. Neuroepidemiology 22: 316-325.
30. Alperovitch A, Bertrand M, Jougla E, Vidal JS, Ducimetiere P, et al. (2009) Do we really know the cause of death of the very old? Comparison between official mortality statistics and cohort study classification. Eur J Epidemiol 24: 669-675.
31. Ioannidis JP, Stavrou I, Trikalinos TA, Zois C, Brandi ML, et al. (2002) Association of polymorphisms of the estrogen receptor alpha gene with bone mineral density and fracture risk in women: a meta-analysis. J Bone Miner Res 17: 2048-2060.
32. Shearman AM, Cupples LA, Demissie S, Peter I, Schmid CH, et al. (2003) Association between estrogen receptor alpha gene variation and cardiovascular disease. JAMA 290: 2263-2270.
33. Slattery ML, Sweeney C, Herrick J, Wolff R, Baumgartner K, et al. (2007) ESR1, AR, body size, and breast cancer risk in Hispanic and non-Hispanic white women living in the Southwestern United States. Breast Cancer Res Treat 105: 327-335.
34. Alonso P, Gratacos M, Segalas C, Escaramis G, Real E, et al. (2011) Variants in estrogen receptor alpha gene are associated with phenotypical expression of obsessive-compulsive disorder. Psychoneuroendocrinology 36: 473-483.
35. Maruyama H, Toji H, Harrington CR, Sasaki K, Izumi Y, et al. (2000) Lack of an association of estrogen receptor alpha gene polymorphisms and transcriptional activity with Alzheimer disease. Arch Neurol 57: 236-240.
36. Rexrode KM, Ridker PM, Hegener HH, Buring JE, Manson JE, et al. (2007) Polymorphisms and haplotypes of the estrogen receptor-beta gene (ESR2) and cardiovascular disease in men and women. Clin Chem 53: 1749-1756.
37. Radloff L, (1977) The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Measurement 1: 385-401.
38. Lawton MP, Brody EM, (1969) Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 9: 179-186.
39. Folstein MF, Folstein SE, McHugh PR, (1975) "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189-198.
40. Commenges D, Letenneur L, Joly P, Alioum A, Dartigues JF, (1998) Modelling age-specific risk: application to dementia. Stat Med 17: 1973-1988.
41. Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S, et al. (2005) Estrogen therapy and risk of cognitive decline: results from the Women's Estrogen for Stroke Trial (WEST). Am J Obstet Gynecol 192: 387-393.
42. Fournier A, Mesrine S, Boutron-Ruault MC, Clavel-Chapelon F, (2009) Estrogen-progestagen menopausal hormone therapy and breast cancer: does delay from menopause onset to treatment initiation influence risks? J Clin Oncol 27: 5138-5143.
43. Prentice RL, Manson JE, Langer RD, Anderson GL, Pettinger M, et al. (2009) Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause. Am J Epidemiol 170: 12-23.
44. Chen GG, Zeng Q, Tse GM, (2008) Estrogen and its receptors in cancer. Med Res Rev 28: 954-974.
45. Kobayashi N, Fujino T, Shirogane T, Furuta I, Kobamatsu Y, et al. (2002) Estrogen receptor alpha polymorphism as a genetic marker for bone loss, vertebral fractures and susceptibility to estrogen. Maturitas 41: 193-201.
46. Domingues-Montanari S, Subirana I, Tomas M, Marrugat J, Senti M, (2008) Association between ESR2 Genetic Variants and Risk of Myocardial Infarction. Clin Chem 54: 1183-1189.
47. Ryan J, Carriere I, Scali J, Ritchie K, Ancelin ML, (2008) Lifetime hormonal factors may predict late-life depression in women. Int Psychogeriatr 20: 1203-1218.